Healius (ASX:HLS) has spent the past 18 months shrinking itself back to a single idea. The imaging arm is gone, the corporate centre has been cut, and what remains is one of Australia's two national pathology networks running on thin margins. On 19 August 2026 the company will put a full year of that reset on the table.
The stock price was in the spotlight after its share price recorded a significant jump. Healius confirmed the timing of its FY26 results in an ASX announcement lodged on 30 July 2026, following a difficult 12 months for shareholders.
What happened?
The defining event of the past year was not a result but a downgrade. On 13 May 2026, Healius issued a trading update for FY26 alongside a strategic review of assets, and the market response was severe.
Healius guided to group underlying EBITDA of $259.0 million to $264.0 million and group underlying EBIT of $30.0 million to $35.0 million for FY26. Pathology volumes, which had grown 1.2% in the first half, were down 0.4% for the ten months to April, while pathology Revenue growth slowed from 3.5% to 2.4% year to date. The same announcement confirmed Healius had engaged an adviser to explore a sale of Agilex Biolabs, its bioanalytical laboratory business.
The story behind the numbers
The half-year result released on 18 February 2026 is the most recent full picture. Group revenue rose 3.8% to $688.1 million, with pathology contributing $666.3 million, up 3.5%. Underlying EBITDA improved 13.1% to $122.2 million and underlying EBIT swung to a positive $7.9 million from a $2.7 million loss a year earlier. The statutory result was still a net loss after tax of $30.4 million.
Pathology EBIT of $5.2 million on $666.3 million of revenue equates to a 0.8% margin, the number that frames the Investment debate. Management is targeting high single-digit EBIT margins by June 2027. Agilex Biolabs was the bright spot, with revenue up 16.0% to $21.8 million and EBIT up 145.5% to $2.7 million.
Why this matters
Healius is no longer a diversified healthcare group. The Lumus Imaging sale to Affinity Equity Partners completed on 1 May 2025 at an Enterprise value of $965 million. What is left is a pathology pure play with a small contract research tail — a scale Business with a national collection footprint, but one where the price of most tests is set by government, leaving cost control as effectively the only lever management holds.
What is driving the investment case?
The thesis rests on operating leverage. Healius has removed roughly 400 full-time equivalent roles, banked $10.7 million of annualised savings in the first half against a $15 million to $20 million program target, and completed a multi-year digital transformation. Genomics revenue rose 21.6% and Clinical Trials revenue jumped 118.6% in the half.
The bull case
If FY26 lands within guidance, Healius will have delivered underlying EBIT of $30 million to $35 million. Add a successful Agilex divestment and the Balance Sheet gains another cushion.
The bear case
The Margin is razor thin and the cost side is moving the wrong way. A gender-based undervaluation decision reclassified pathology collectors and added $1.8 million of cost in the June quarter alone, with further increases phased in from 2027. Volumes are soft, and net cash of just $11.6 million at the half leaves no longer a large buffer to absorb execution error.
What could move the share price next?
The FY26 result on 19 August 2026 is the immediate event, and the company has said it will provide an Agilex update at the same time. Director nominations for the 2026 AGM close on 20 August 2026, with the meeting set for 22 October 2026.
Outlook
Healius enters this week as a genuinely contested stock. The restructuring is measurable and the asset base is simpler than it has been in years, but a 0.8% half-year divisional margin leaves almost no room for error, and wage and indexation pressures look structural rather than cyclical.
_11_17_2026_06_50_14_402066.jpg)





Please wait processing your request...